tiprankstipranks
Advertisement
Advertisement
Early Cancer Drug Trial Termination Highlights Pipeline Risk for BeOne Medicines (ONC)
PremiumCompany AnnouncementsEarly Cancer Drug Trial Termination Highlights Pipeline Risk for BeOne Medicines (ONC)
17d ago
BeOne Medicines downgraded to Hold from Buy at Jefferies
Premium
The Fly
BeOne Medicines downgraded to Hold from Buy at Jefferies
18d ago
BeiGene Terminates Early-Stage Solid Tumor Trial, Shifting Risk Focus for Oncology Investors
Premium
Company Announcements
BeiGene Terminates Early-Stage Solid Tumor Trial, Shifting Risk Focus for Oncology Investors
20d ago
BeOne Medicines price target raised to $405 from $394 at Barclays
PremiumThe FlyBeOne Medicines price target raised to $405 from $394 at Barclays
1M ago
BeOne Medicines reports Q4 adjusted EPS $1.95, consensus $1.30
Premium
The Fly
BeOne Medicines reports Q4 adjusted EPS $1.95, consensus $1.30
1M ago
BeOne Medicines sees 2026 revenue $6.2B-$6.4B, consensus $6.44B
Premium
The Fly
BeOne Medicines sees 2026 revenue $6.2B-$6.4B, consensus $6.44B
1M ago
BeiGene’s BGB-24714 Solid Tumor Trial Terminated: What It Means for Oncology Investors
PremiumCompany AnnouncementsBeiGene’s BGB-24714 Solid Tumor Trial Terminated: What It Means for Oncology Investors
2M ago
BeOne Medicines Targets CLL Leaders With New Phase 3 Head-to-Head Trial
Premium
Company Announcements
BeOne Medicines Targets CLL Leaders With New Phase 3 Head-to-Head Trial
3M ago
BeOne Medicines upgraded to Outperform from Market Perform at Bernstein
Premium
The Fly
BeOne Medicines upgraded to Outperform from Market Perform at Bernstein
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100